<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02248883</url>
  </required_header>
  <id_info>
    <org_study_id>1182.60</org_study_id>
    <nct_id>NCT02248883</nct_id>
  </id_info>
  <brief_title>Electrophysiological Effects of Tipranavir Co-administered With Ritonavir on the QT Interval in Healthy Female and Male Subjects</brief_title>
  <official_title>Assessment of Electrophysiological Effects of Tipranavir Co-administered With Ritonavir Given b.i.d. for 2.5 Days on the QT Interval in Healthy Female and Male Subjects. A Double-blind, Randomised, Placebo Controlled, Two-way Crossover Study With a Positive Control (Moxifloxacin) and Parallel Dose Groups</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To demonstrate that tipranavir (TPV) co-administered with ritonavir (RTV) does not affect the
      QT interval more than placebo co-administered with ritonavir
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in individually heart rate corrected QT interval length (QTcI)</measure>
    <time_frame>baseline and 2 to 4 hours after drug administration on day3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in (QTcI)</measure>
    <time_frame>baseline and 2 to 4 hours after drug administration on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in (QTcI)</measure>
    <time_frame>baseline and 1 to 12 hours after drug administration on day1 and 3</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>low TPV/RTV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>high TPV/RTV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/RTV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPV low</intervention_name>
    <arm_group_label>low TPV/RTV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo/RTV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <arm_group_label>low TPV/RTV</arm_group_label>
    <arm_group_label>high TPV/RTV</arm_group_label>
    <arm_group_label>Placebo/RTV</arm_group_label>
    <other_name>Avelox®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPV high</intervention_name>
    <arm_group_label>high TPV/RTV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RTV</intervention_name>
    <arm_group_label>low TPV/RTV</arm_group_label>
    <arm_group_label>high TPV/RTV</arm_group_label>
    <arm_group_label>Placebo/RTV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy female and male volunteers as determined by the results of screening according
             to the following criteria: Based upon a complete medical history, including the
             physical examination, vital signs (BP, HR), 12-lead ECG, clinical laboratory tests

          2. Age ≥ 18 and Age ≤ 55 years

          3. BMI ≥ 18.5 and BMI ≤ 29.9 kg/m2 (Body Mass Index)

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and the local legislation

        Exclusion Criteria:

          1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          2. Gastrointestinal tract surgery (except appendectomy)

          3. Diseases of the central nervous system (such as epilepsy, seizures) or psychiatric
             disorders or neurological disorders

          4. History of relevant orthostatic hypotension, fainting spells or blackouts.

          5. Relevant acute, chronic or active chronic infections (e.g. hepatitis, HIV).

          6. History of allergy/hypersensitivity (including drug allergies) that are deemed
             relevant to the trial as judged by the investigator

          7. Intake of drugs with a long half-life (&gt;24 hours) within at least one month or less
             than 10 half-lives of the respective drug prior to administration or during the trial

          8. Use of drugs which might reasonably influence the results of the trial based on the
             knowledge at the time of protocol preparation within 10 days prior to administration
             or during the trial

          9. Participation in another trial with an investigational drug within two months prior to
             administration or during the trial

         10. Smoker (more than 10 cigarettes/day or 3 cigars/day or 3 pipes/day)

         11. Inability to refrain from smoking on trial days

         12. Alcohol abuse (more than 60 g/day)

         13. Drug abuse

         14. Veins unsuited for i.v. puncture on either arm (e.g. veins which are difficult to
             locate, access or puncture, veins with a tendency to rupture during or after puncture)

         15. Blood donation (more than 100 mL within four weeks prior to administration or during
             the trial)

         16. History of any bleeding disorder or acute blood coagulation defect

         17. Hypersensitivity to ritonavir, moxifloxacin and/or related drugs of these classes

         18. History of Glucose-6-phosphate-deficiency

         19. Excessive physical activities (within one week prior to trial or during the trial)

         20. Any laboratory value outside the reference range that is of clinical relevance

         21. A history of additional risk factors for torsade de pointes (TdP) (e.g., heart
             failure, hypokalemia, family history of Long QT Syndrome)

         22. Heart rate at screening of &gt; 80 bpm or &lt; 45 bpm

         23. Any screening ECG value outside of the reference range of clinical relevance
             including, but not limited to PR interval &gt; 240 ms, QRS interval &gt; 120 ms, QTcB or
             QTcF &gt; 450 ms, or QT (uncorrected) &gt; 470 ms

         24. Inability to comply with the dietary regimen of the study centre

             For female subjects:

         25. Pregnancy

         26. Positive pregnancy test

         27. No adequate contraception (adequate contraception e.g. sterilisation, intrauterine
             pessary (IUP) or oral contraception not containing ethinyl estradiol)

         28. Oral contraception containing ethinyl estradiol without the use of an additional
             barrier method

         29. Hormone replacement containing ethinyl estradiol

         30. Inability to maintain this adequate contraception during the whole study period

         31. Lactation period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2014</study_first_submitted>
  <study_first_submitted_qc>September 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2014</study_first_posted>
  <last_update_submitted>September 24, 2014</last_update_submitted>
  <last_update_submitted_qc>September 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Tipranavir</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

